The long term goal is to elucidate the processes by which mitogenic signals are relayed intracellularly, and to apply this information to understanding how normal growth control is deregulated enabling the progression of lung cancer. Among the differences between normal and tumor lung cells is that the tumor cells secrete increased concentrations of growth factors, which in some instances drive the increased growth rate of the tumors. Thus one of the mechanisms by which normal lung tissue becomes tumorigenic involves increased concentrations of growth factors. However, increased concentrations of growth factors alone are probably not enough to cause lung tumors, since chronic stimulation of tissue culture cells with high levels of growth factors does not usually lead to transformation. More often, cells become transformed when they overexpress and/or harbor mutations within their growth factor receptors. The short-term goal, to be addressed in this research proposal, is to test whether progression of normal lung cells to the malignant state involves both the increased production of growth factors and the mutation and/or overexpression of growth factor receptors. The first specific aim will define the incidence of overexpression and mutation of known growth factor receptors, while the second specific aim will focus on identifying novel lung-specific receptor tyrosine kinases. In the third specific aim, the biological significance of the first two specific aims will be tested. The mutant and novel receptors will be expressed in normal lung tissue to test whether they act as oncogenes. The effect of growth factor stimulation on the ability to transform will also be determined. Finally, we will test the contribution of the identified growth factor receptors to the progression of lung cells from the premalignant to the tumorigenic state. The direct benefit of understanding the role of growth factors and their receptors in the progression of lung tumors will significantly contribute to both prognosis of the stage of a lung tumor, as well as the treatment and management of lung tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA058187-01
Application #
3796265
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Patil, Tejas; Smith, Derek E; Bunn, Paul A et al. (2018) The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. J Thorac Oncol 13:1717-1726
Suda, Kenichi; Kim, Jihye; Murakami, Isao et al. (2018) Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions. J Thorac Oncol 13:1496-1507
Helfrich, Barbara A; Gao, Dexiang; Bunn Jr, Paul A (2018) Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy. Lung Cancer 118:148-154
Kleczko, Emily K; Heasley, Lynn E (2018) Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Mol Cancer 17:60
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739
Pilling, Amanda B; Kim, Jihye; Estrada-Bernal, Adriana et al. (2018) ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget 9:8823-8835
Kwak, Jeff W; Laskowski, Jennifer; Li, Howard Y et al. (2018) Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. Cancer Res 78:143-156
Sakamoto, Mandy R; Honce, Justin M; Lindquist, Deborah L et al. (2018) Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib. Clin Lung Cancer :
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770

Showing the most recent 10 out of 435 publications